Recap of Avisi CEO’s Participation in Two Impactful Panels at LSI Emerging Medtech Summit Avisi Technologies returns to the Life Science Intelligence (LSI) stage with CEO Rui Jing Jiang participating in several panel discussions at the 2025 MedTech Summit. The panel discussions involved leadership and design strategies for achieving success within the MedTech industry. Life […]
In an article by Glaucoma Physician, Jim Gallagher reports on the positive six-month results for VisiPlate® from the VITA trial presented by Dr. Eydie Miller-Ellis at the American Glaucoma Society (AGS). This was considered a top paper by the society and presented during the Surgery Day Paper Presentation at AGS. Dr. Miller-Ellis serves as the […]
Some medtech start-ups begin with an inventor with a novel idea; others seek out an unmet clinical need looking for a solution. Avisi Technologies began with market research, that is, a direct appeal to glaucoma specialists to determine what they were missing in their tool kits, and specifically, how the current generation of devices for minimally invasive […]
Summary of Avisi Involvement as Presenting Company 2024 and 2023 Panel Representation Avisi Technologies returned to the 2024 US Emerging Medtech Summit with updates about the development of VisiPlate, a nanotechnology-enabled aqueous shunt for the treatment of glaucoma. Avisi generated buzz in the Life Science Intelligence (LSI) community by announcing exclusive clinical data, showing promising […]
Interim trial results demonstrate the safety and effectiveness of VisiPlate® as a standalone treatment for primary open-angle glaucoma. REDWOOD CITY, Calif., (May 14, 2024) – Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant […]
Avisi Technologies has been shortlisted for Junkosha’s second-year Innovator of the Year Award program. This year had a tremendous number of applicants with Avisi Technologies being 1 of the 11 shortlisted to impress the panel of expert judges chosen for their vast industry experience in medical devices. The winning company will be awarded a $25,000 […]
Avisi, a trailblazing medical device company, is developing VisiPlate, a nanotechnology-enabled aqueous shunt designed to treat glaucoma. Working closely with ophthalmologists and experts, Avisi is committed to introducing a reliable, safe and effective solution for glaucoma patients.
The company — a 2020 RealLIST Startups honoree — aims to treat open-angle glaucoma with an ocular implant that’s designed to remove excess fluid from inside the eye. Its recent funding injection totals just over $4 million.
At Just Funded Media we track over 1,000,000 recently funded startups and over 3,800,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and organisations we think deserve more appreciation than they are currently getting.
